Peplin completes Neosil buy
Monday, 20 October, 2008
Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.
The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.
Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.
Genetics shape our personality and life outcomes more than we thought
Scientists have identified more than 1200 genetic variants associated with personality traits,...
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
